Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial

被引：0
|
作者：
Ettinger, D. S. [1 ]
Jotte, R. [2 ]
Lorigan, P. [3 ]
Gupta, V. [4 ]
Garbo, L. [5 ]
Spigel, D. [6 ]
Dudek, A. Z. [7 ]
Salgia, R. [8 ]
McNally, R. [9 ]
Renschler, M. [10 ]
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Rocky Mt Canc Ctr US Oncol, Denver, CO USA
[3] Christie Hosp, NHS Fdn Trust, Manchester, Lancs, England
[4] St Joseph Oncol US Oncol, St Joseph, MO USA
[5] New York Oncol Hematol US Oncol, Albany, NY USA
[6] Sarah Cannon Canc Ctr, Nashville, TN USA
[7] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Celgene Corp, Biostat, Summit, NJ USA
[10] Celgene Corp, Clin Dev, Summit, NJ USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71834-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：541 / 541
页数：1
相关论文
共 50 条
  • [21] Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): Final results of a randomised phase III trial
    Heigener, D. F.
    Freitag, L.
    Eschbach, C.
    Huber, R. M.
    Fink, T.
    Hummler, S.
    Banik, N.
    Wolf, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] A phase II trial in patients with extensive disease small-cell lung cancer (ED-SCLC) with irinotecan, carboplatin and etoposide regimen as a front line treatment
    Syrigos, Konstantinos N.
    Charpidou, Andriani G.
    Pantazopoulos, Kosmas N.
    Dilana, Kalliopi
    Rigopoulou, Anna
    Georgatou, Niki
    Roussos, Charalampos
    ANNALS OF ONCOLOGY, 2006, 17 : 232 - 232
  • [23] TOTAL COST OF CARE AMONG PATIENTS WITH EXTENSIVE DISEASE SMALL CELL LUNG CANCER (ED-SCLC)
    Danese, M.
    Gleeson, M.
    Lubeck, D.
    Bobiak, S.
    VALUE IN HEALTH, 2017, 20 (05) : A358 - A358
  • [24] Phase I trial of the novel epothilone sagopilone (ZK-EPO) in combination with cisplatin as first-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)
    Gauler, T. C.
    Christoph, D. C.
    Gamarra, F.
    Fuhr, H.
    Gonschorek, C.
    Giurescu, M.
    Frickhofen, N.
    Huber, R. M.
    Schuler, M.
    Eberhardt, W. E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Phase II trial of huKS-IL2 with cyclophosphamide (CTX) in patients with extensive disease small-cell lung cancer (ED-SCLC)
    Gladkov, Oleg
    Biakhov, Mikhail
    Ramlau, Rodryg
    Serwatowski, Piotr
    Milanowski, Janusz
    Tomeczko, Janusz
    Komarnitsky, Philip B.
    Bernard, Laurence
    Kramer, Daniel
    Krzakowski, Maciej Jerzy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Treatment patterns and survival among patients with extensive disease small cell lung cancer (ED-SCLC).
    Danese, Mark D.
    Gleeson, Michelle L.
    Lubeck, Deborah P.
    Korytowsky, Beata
    Bobiak, Sarah
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
    Jotte, Robert
    Conkling, Paul
    Reynolds, Craig
    Galsky, Matthew D.
    Klein, Leonard
    Fitzgibbons, James F.
    McNally, Richard
    Renschler, Markus F.
    Oliver, Jennifer W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : 287 - 293
  • [28] Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)
    Reck, M.
    Horn, L.
    Novello, S.
    Barlesi, F.
    Albert, I.
    Juhasz, E.
    Chung, J.
    Fritsch, A.
    Drews, U.
    Rutstein, M.
    Wagner, A.
    Govindan, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
    Cheng, Y.
    Wang, J.
    Cang, S.
    Cao, L.
    Chen, E.
    Dong, X.
    Fan, Y.
    Gao, B.
    Guo, Q.
    Huang, D.
    Li, S.
    Liu, A.
    Lv, D.
    Pan, Y.
    Tang, K.
    Yao, W.
    Ye, F.
    Yu, Y.
    Zang, A.
    Gao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S727 - S728
  • [30] Phase I trial of sagopilone in combination with cisplatin as 1st-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)
    Christoph, D. C.
    Gauler, T. C.
    Gamarra, F.
    Fuhr, H. G.
    Fischer, J. R.
    Gonschorek, C.
    Frickhofen, N.
    Huber, R. M.
    Schuler, M.
    Eberhardt, W. E. E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 542 - 542
12345